Intraperitoneal Carboplatin with or without Interferon-α in Advanced Ovarian Cancer Patients with Minimal Residual Disease at Second Look: A Prospective Randomized Trial of 111 Patients
- 30 June 1997
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 65 (3) , 499-505
- https://doi.org/10.1006/gyno.1997.4689
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Intraperitoneal immunotherapy for ovarian cancer with alpha interferonEuropean Journal Of Cancer, 1992
- Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferonGynecologic Oncology, 1992
- A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancerEuropean Journal Of Cancer, 1992
- Experience with Intraperitoneal Alpha-2a InterferonOncology, 1992
- Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second lookGynecologic Oncology, 1990
- A phase I–II trial of intraperitoneal cisplatin and α-lnterferon in patients with persistent epithelial ovarian cancerGynecologic Oncology, 1990
- Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1990
- High-dose melphalan and autologous bone marrow support for treatment of ovarian carcinoma with positive second-look operationGynecologic Oncology, 1989
- Clinical Trials: Design, Conduct, and Analysis.Journal of the American Statistical Association, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958